TRNS vs. TXG, CTKB, EYPT, LAB, SENS, ALNT, QSI, AEHR, QTRX, and MASS
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include 10x Genomics (TXG), Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Senseonics (SENS), Allient (ALNT), Quantum-Si (QSI), Aehr Test Systems (AEHR), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Transcat vs.
Transcat (NASDAQ:TRNS) and 10x Genomics (NASDAQ:TXG) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.
In the previous week, 10x Genomics had 7 more articles in the media than Transcat. MarketBeat recorded 11 mentions for 10x Genomics and 4 mentions for Transcat. 10x Genomics' average media sentiment score of 1.00 beat Transcat's score of 0.39 indicating that 10x Genomics is being referred to more favorably in the news media.
Transcat received 150 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 66.14% of users gave Transcat an outperform vote while only 51.26% of users gave 10x Genomics an outperform vote.
Transcat has a net margin of 6.22% compared to 10x Genomics' net margin of -29.90%. Transcat's return on equity of 7.23% beat 10x Genomics' return on equity.
Transcat has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Transcat has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Transcat currently has a consensus price target of $111.50, suggesting a potential upside of 56.93%. 10x Genomics has a consensus price target of $20.21, suggesting a potential upside of 107.33%. Given 10x Genomics' higher probable upside, analysts plainly believe 10x Genomics is more favorable than Transcat.
98.3% of Transcat shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 2.3% of Transcat shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Transcat beats 10x Genomics on 11 of the 18 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy TRNS Stock Free TRNS Stock Alerts